Guardion Health Sciences Announces Submission of Patent Application for Treatment of Certain Underlying Conditions Related to...
July 08 2020 - 8:45AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), a specialty health sciences company that develops
medical foods and medical devices in the ocular health marketplace
and which is developing nutraceuticals it believes will provide
medicinal and health benefits to consumers, announced that it has
submitted a formal patent application to the U.S. Patent and
Trademark Office seeking to protect its proprietary formula,
currently marketed by Guardion as GlaucoCetin. GlaucoCetin provides
nutritional support to help manage certain underlying conditions
related to eye disease. The Company previously submitted a
provisional patent to the U.S. Patent and Trademark Office on June
11, 2019.
The invention, “Compositions for Improved
Neuroprotective Effects and Methods of Making Same,” relates to a
nutritional formula designed to reverse mitochondrial dysfunction
in nerve cells – mitochondrial dysfunction is now thought to be a
contributing factor to vision loss in patients with glaucoma. Dr.
Robert Ritch, M.D., the inventor of the formula, is a
world-renowned glaucoma scientist and clinician and is a member of
the Guardion Medical Advisory Board. Dr. Ritch holds the
Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and
is Surgeon Director Emeritus and Chief of Glaucoma Services at the
New York Eye & Ear Infirmary of Mount Sinai, New York City and
Professor of Ophthalmology.
“We are pleased to announce that we have
filed this patent application to establish meaningful legal
protection for this novel formula designed to manage a potential
underlying cause of vision loss from eye disease,” said Dr. David
Evans, Ph.D., Guardion’s Interim President and Chief Executive
Officer. “GlaucoCetin joins Guardion’s other medical food,
Lumega-Z®, as a targeted nutritional therapy designed to assist
patients in managing their health as they age, and offers an
additional opportunity for Guardion to expand its market position
in the nutrition industry, both in the United States and
abroad.”
Also, as previously announced on June 30, 2020,
Guardion has completed delivery of an $875,000 order for Astramern,
its novel nutraceutical formulation designed to support the body’s
immune function, to Astramune Sdn Bhd, a subsidiary of Ho Wah
Genting Berhad (“HWGB”) (KLSE:9601), a Malaysian company listed on
the Malaysian Stock Exchange (Industrial Products sector). Guardion
will recognize this shipment in operating revenues for the three
months ended June 30, 2020.
About Guardion Health Sciences,
Inc.
Guardion is a specialty health sciences company
(i) that develops medical foods and medical devices in the ocular
health marketplace and (ii) that is developing nutraceuticals that
the Company believes will provide medicinal and health benefits to
consumers. Information and risk factors with respect to Guardion
and its business, including its ability to successfully develop and
commercialize its proprietary products and technologies, may be
obtained in the Company’s filings with the SEC at www.sec.gov.
About NutriGuard™
NutriGuard™ formulates high-quality
nutraceuticals which are designed to supplement consumers’ diets.
NutriGuard uses industry standards to establish the safety and
efficacy of the products it develops and markets, maintains that
commitment through prudent manufacturing and quality assurance
programs, and only uses manufacturers who comply with FDA current
Good Manufacturing Practices (cGMP) requirements. Guardion plans to
increase NutriGuard’s existing customer base and build on its
product platform by making NutriGuard products available to
patients directly and through recommendations by their
physicians.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision’s®
patented technology is considered the standard of care for clinical
trials. VectorVision® is a wholly owned subsidiary of Guardion.
Forward-Looking Statement Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but not limited to, the Company’s ability to
raise sufficient financing to implement its business plan, the
impact of the COVID-19 pandemic on the Company’s business,
operations and the economy in general, and the Company’s ability to
successfully develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward- looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations Contact:
Porter, LeVay & Rose, Inc.
Michael PorterTelephone:(212) 564-4700 E-mail:
mike@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024